Altimmune, Inc. (ALT) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts ALT Hot Sheet
Join SI Premium – FREE
Altimmune, Inc. (NASDAQ: ALT) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $5 thousand versus the consensus estimate of $714 million.
For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corning (GLW) files for up to $2B offering of common shares
- Zenas BioPharma (ZBIO) files for up to 7M share offering by selling stockholders
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
